Fibroblast Activation Protein Expression in Sarcomas

Table 4

Active clinical trials investigating therapeutics targeting FAP for which patients with sarcoma may be eligible.

Intervention	Intervention type	Study population	Phase	NCT number
177-Lu-FAP-2286	Peptide-targeted radionuclide therapy	Adults with refractory/progressive advanced/metastatic solid tumors	Phase 1/2	NCT04939610
MP0317	Designed ankyrin repeat protein (DARPin®) drug targeting FAP and CD40	Adults with relapsed/refractory advanced solid tumors	Phase 1	NCT05098405
RO7300490 as a single agent or combined with atezolizumab	RO7300490 is a bispecific antibody	Adults with advanced solid tumors	Phase 1	NCT04857138
RO6874281 as a single agent or combined with trastuzumab or cetuximab	RO6874281 is a bispecific targeted IL-2 variant with the antibody component targeted against FAP	Adults with advanced/metastatic solid tumors	Phase 1	NCT02627274
Nectin4/FAP targeted fourth-generation CAR-T cells	CAR-T	Adults with advanced malignant solid tumors	Phase 1	NCT03932565

Abbreviation key: FAP = fibroblast activation protein; CAR-T: chimeric antigen receptor (CAR)-T cell therapies.